Compare PMCB & DFNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | DFNS |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.2M |
| IPO Year | 2001 | 2020 |
| Metric | PMCB | DFNS |
|---|---|---|
| Price | $0.42 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 97.6K | ★ 555.2K |
| Earning Date | 12-17-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 261.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,913,461.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $1.75 |
| 52 Week High | $1.51 | $335.00 |
| Indicator | PMCB | DFNS |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 28.60 |
| Support Level | $0.32 | N/A |
| Resistance Level | $0.77 | $7.36 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 91.64 | 20.25 |
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. The company operates as a strategic platform, building a portfolio of mission-critical suppliers and technology companies. Its portfolio includes businesses involved in defense and aerospace technologies, such as AI software, unmanned aerial systems, electro-mechanical manufacturing, and motion control systems, as well as activities in technology distribution, licensing, and defense infrastructure development through joint ventures.